Navigator Medicines

What Navigator Medicines does

Navigator Medicines is a clinical-stage biotechnology company developing bispecific antibodies for inflammatory and autoimmune diseases. Founded in 2024 as a subsidiary of Sera Medicines and headquartered in Scotch Plains, New Jersey, the company focuses on a dual-mechanism approach: simultaneously inhibiting OX40L and TNFα, two clinically validated drivers of inflammation. Its lead candidate, NAV-240, is a tetravalent bispecific antibody currently in Phase 2a development for hidradenitis suppurativa (the MAINSAIL trial), with additional planned indications in Crohn's disease and ulcerative colitis. A second clinical-stage asset, NAV-242, is a next-generation, half-life extended bispecific antibody engineered to enable every-other-month or quarterly subcutaneous dosing; it entered Phase 1 in March 2026 following Australian HREC approval.

The company's technology rests on a proprietary OX40L/TNFα bispecific platform, with NAV-240 originally in-licensed from IMBiologics Corp. in August 2024 as part of a $100 million Series A co-led by RA Capital Management and Forbion. By blocking OX40L alongside TNFα, the platform is designed to dampen inflammation without compromising baseline T-cell populations essential for long-term immune health, addressing a clear unmet need in hidradenitis suppurativa where only three in ten patients achieve meaningful symptom relief on existing biologics. The business model is that of a traditional clinical-stage biotech: Navigator generates no current product revenue and is funded by equity capital intended to advance candidates through FDA-regulated clinical trials toward eventual regulatory approval and commercialization, at which point revenue would be generated through prescription biologic sales or out-licensing. Phase 1a single ascending dose data (September 2025) and Phase 1b multiple ascending dose data (presented at AAD 2026) have shown favorable safety, predictable pharmacokinetics, and low immunogenicity in healthy volunteers, with Phase 2a MAINSAIL topline results expected in the second half of 2027 to inform pivotal development.

Name

Navigator Medicines

Legal name

Navigator Medicines, Inc.

Website

https://navigatormedicines.com

Company type

Private

Founded year

2024

Operating status

Operating

Headcount range

11–50 employees

Short description

Navigator Medicines is a clinical-stage biotech founded in 2024 developing bispecific antibodies (NAV-240 and NAV-242) that simultaneously target OX40L and TNFα for patients with hidradenitis suppurativa, Crohn's disease, and ulcerative colitis.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals

NAICS

Scientific Research and Development Services (5417)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)

akta.pro secondary industry

Gastroenterology Specialty Pharmaceuticals (HLAIACAE)

Keywords

• Bispecific antibodies
• Autoimmune disease therapeutics
• Inflammatory disease drug development
• Clinical-stage biotechnology
• Dual pathway inhibition

Headquarters

HQ city

Scotch Plains

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations

Revenue model

1. Pharmaceutical Development and Commercialization: Navigator Medicines is a clinical-stage biotech company with no current revenue. The company is developing bispecific antibody therapeutics (NAV-240 and NAV-242) for inflammatory and autoimmune diseases. Revenue will be generated upon successful clinical development and regulatory approval of its pipeline candidates, with initial focus on hidradenitis suppurativa, Crohn's disease, and ulcerative colitis.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Navigator Medicines is a clinical-stage biotech company developing bispecific antibody therapeutics (NAV-240 and NAV-242) that simultaneously target OX40L and TNFα to treat inflammatory and autoimmune diseases, with initial focus on hidradenitis suppurativa, Crohn's disease, and ulcerative colitis. The pipeline candidates are designed to deliver superior efficacy over single-pathway biologics, with NAV-242 offering extended half-life for convenient dosing.

Product overview

Navigator Medicines is a clinical-stage biotech company advancing a pipeline of bispecific antibodies targeting OX40L and TNFα for inflammatory and autoimmune diseases. The company's portfolio consists of two clinical-stage bispecific antibody candidates: NAV-240 (Phase 2a) and NAV-242 (Phase 1), both targeting the same dual mechanism of OX40L and TNFα inhibition but differentiated by NAV-242's half-life extension technology for improved dosing convenience. The company focuses on areas of high unmet need, particularly hidradenitis suppurativa, Crohn's disease, and ulcerative colitis.

Differentiator

Problem solved

Functional benefit

Products and services

• NAV-240 NAV-240 is a clinical-stage bispecific antibody targeting OX40L and TNFα for treating inflammatory and autoimmune diseases, particularly hidradenitis suppurativa. The tetravalent antibody format enables dual inhibition of both pathways to improve upon efficacy of either monotherapy alone. Currently in Phase 2a development (MAINSAIL trial) following FDA IND clearance.
• NAV-242 NAV-242 is a next-generation, clinical-stage bispecific antibody designed to simultaneously inhibit OX40L and TNFα with extended half-life for optimized dosing. Engineered for subcutaneous administration with potential for every other month or quarterly dosing for conditions including hidradenitis suppurativa, Crohn's disease, and ulcerative colitis. Currently in Phase 1 development.

Quantifiable outcome

• Phase 2a MAINSAIL trial results expected in H2 2027 to support pivotal development
• +2 more outcomes

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Two partnerships are on record, tiered core.

• IMBiologics Corp.coreStrategic or Co-development Partner · 27 August 2024Navigator Medicines in-licensed NAV-240 (formerly IMB101) and an OX40L-targeted portfolio from IMBiologics Corp. as part of the August 2024 Series A financing transaction. This in-licensing agreement provided Navigator with its lead clinical candidate and foundational intellectual property for the bispecific antibody program.
• Sera MedicinescoreOthers · 1 January 2024Navigator Medicines was founded in 2024 as a subsidiary of Sera Medicines. The company operates as an independent entity with its own leadership team and financing, but maintains a parent-subsidiary relationship with Sera Medicines.

Scale indicators4 records

Recent moves7 records

Expansion highlights5 records

Broad incumbents

• Sanofi: Sanofi is developing amlitelimab, an anti-OX40L monoclonal antibody, in late-stage clinical trials for atopic dermatitis and other inflammatory conditions. As a major pharma with deep immunology commercial infrastructure (Dupixent), Sanofi is both a direct competitor in OX40L and a likely strategic acquirer of clinical-stage immunology assets.
• Amgen: Amgen is a major inflammation/immunology player (Enbrel, Otezla, Tezspire) with deep anti-TNFα and broader immunology expertise. The company acquired ChemoCentryx — the prior employer of Navigator's CEO — and is a likely strategic acquirer of differentiated immunology assets.
• Novartis: Novartis is a major immunology player (Cosentyx for HS and other inflammatory diseases) and acquired Gyroscope Therapeutics — the prior company of Navigator's Chairman. Novartis is a direct competitor in HS via Cosentyx and a likely strategic acquirer.
• AbbVie: AbbVie markets Humira (adalimumab) — the dominant anti-TNFα biologic — as well as Skyrizi and Rinvoq across inflammatory diseases including HS (via Humira). AbbVie is the entrenched standard-of-care in HS and across inflammatory disease, and serves as the primary incumbent benchmark for efficacy and commercial positioning.
• GSK: GSK is a major immunology player (Nucala, Benlysta) and acquired Aiolos Bio — the prior company of Navigator's Chairman. GSK is both a likely strategic acquirer and a major pharma with overlapping inflammatory disease development expertise.

Emerging players

• Kymera Therapeutics: Kymera is a clinical-stage biotech developing immunology and inflammation programs using targeted protein degradation (including KT-474 for HS and hidradenitis). It is a relevant emerging peer given overlapping disease focus and clinical-stage status.
• AnaptysBio: AnaptysBio is a clinical-stage immunology company with an anti-OX40L program (and broader IL-36R/PD-1 agonist assets). It is a relevant peer given its anti-OX40L antibody development, though focused on a broader set of immuno-oncology and inflammatory disease targets.

Direct peers

• UCB: UCB is developing rocatinlimab, an anti-OX40 monoclonal antibody in Phase 3 for atopic dermatitis and being explored in additional inflammatory indications. It is a direct competitor in the OX40/OX40L pathway for inflammatory disease and a relevant peer for both mechanism and indication overlap.
• Arcutis Biotherapeutics: Arcutis is a commercial-stage dermatology biotech with a topical roflumilast franchise (ZORYVE) including a recent HS program. It is a directly comparable specialty dermatology/immunology peer with overlapping HS commercial interest, though focused on topical rather than injectable biologics.
• MoonLake Immunotherapeutics: MoonLake is a clinical-stage biotech developing sonelokimab, a trivalent Nanobody VHH targeting IL-17A, IL-17F, and albumin, with lead programs in hidradenitis suppurativa. It is the most directly comparable peer — same disease focus (HS), similar bispecific/multivalent antibody modality, and overlapping clinical-stage status as a small-cap immunology biotech.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Navigator Medicines